Rivoceranib Mesylate is the mesylate salt of rivoceranib, an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. Additionally, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases. It is grouped under the following drug class(es): Tyrosine Kinase Inhibitors and VEGF inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Apatinib Mesylate, Aitan and YN968D1. Its PubChem CID is 45139106.
Rivoceranib mesylate
| CAS No | 1218779-75-9 |
|---|---|
| Molecular Formula | C25H27N5O4S |
| Molecular Weight | 493.6 g/mol |
| Synonyms | N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;methanesulfonic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Rivoceranib Mesylate is the mesylate salt of rivoceranib, an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities.
The listed CAS number is 1218779-75-9.
The listed molecular formula is C25H27N5O4S.
The listed molecular weight is 493.6 g/mol.
N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;methanesulfonic acid.
The source lists Apatinib Mesylate, Aitan and YN968D1.